DOSING REGIMEN CHANGES ELIGIBLE FOR THREE-YEAR MARKETING EXCLUSIVITY
This article was originally published in The Tan Sheet
Executive Summary
DOSING REGIMEN CHANGES ELIGIBLE FOR THREE-YEAR MARKETING EXCLUSIVITY under FDA's final rule on the patent and exclusivity provisions of Title I of the Waxman/Hatch act published in the Oct. 3 Federal Register. The final rule becomes effective Nov. 2, 1994. The proposed rule was published on July 10, 1989.